Literature DB >> 6703682

Pharmacokinetics of moxalactam in elderly subjects.

M H Andritz, R P Smith, A L Baltch, P E Griffin, J V Conroy, N Sutphen, M C Hammer.   

Abstract

The pharmacokinetics of moxalactam were studied in 19 male volunteers 60 years of age or older with normal liver function tests and a creatinine clearance of greater than or equal to 60 ml/min. Moxalactam was administered in single or multiple intravenous or intramuscular doses. Rapid and complete intramuscular bioavailability was demonstrated in a subgroup of the study population. The mean plasma half-life was 2.9 +/- 0.8 h for intravenous doses and 3.5 +/- 0.9 h for intramuscular doses. Average renal clearances of 0.04 liters/kg per h accounted for 74.0 +/- 15.0% of total plasma clearance. Moxalactam plasma clearance showed a statistically significant (P less than 0.01) correlation with measured and calculated creatinine clearance. The major differences in moxalactam pharmacokinetics seen in the elderly appear to be related to diminishing renal function and highly variable nonrenal elimination. Creatinine clearance can be used in estimating moxalactam doses in the elderly without significant renal impairment, but recommendations for the use of serum creatinine as an estimation of renal function or drug half-life are not valid in this population group.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6703682      PMCID: PMC185429          DOI: 10.1128/AAC.25.1.33

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1976-10

2.  CSTRIP, a fortran IV computer program for obtaining initial polyexponential parameter estimates.

Authors:  A J Sedman; J G Wagner
Journal:  J Pharm Sci       Date:  1976-07       Impact factor: 3.534

3.  Rapid evaluation of creatinine clearance.

Authors:  K Siersbaek-Nielsen; J M Hansen; J Kampmann; M Kristensen
Journal:  Lancet       Date:  1971-05-29       Impact factor: 79.321

4.  Computer-assisted prescribing of kanamycin for patients with renal insufficiency.

Authors:  G E Mawer; S B Lucas; B R Knowles; R M Stirland
Journal:  Lancet       Date:  1972-01-01       Impact factor: 79.321

5.  Use of a programmable hand-held calculator for clinical pharmacokinetics.

Authors:  T S Foster; D W Bourne
Journal:  Am J Hosp Pharm       Date:  1977-01

Review 6.  Pharmacokinetics in the elderly.

Authors:  J Crooks; K O'Malley; I H Stevenson
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

7.  Steady-state moxalactam kinetics: comparisons with other cephalosporins.

Authors:  P Garzone; J Lyon; V L Yu; J Zuravleff; W Diven; W Pasculle
Journal:  Clin Pharmacol Ther       Date:  1981-07       Impact factor: 6.875

8.  Pharmacokinetics of moxalactam in subjects with various degrees of renal dysfunction.

Authors:  W K Bolton; W M Scheld; D A Spyker; T L Overby; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

9.  Moxalactam pharmacokinetics during hemodialysis.

Authors:  G R Aronoff; R S Sloan; S A Mong; F C Luft; S A Kleit
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191

10.  Pharmacokinetics of moxalactam in patients with renal insufficiency.

Authors:  M Lam; C V Manion; A W Czerwinski
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

View more
  4 in total

Review 1.  Considerations in dosage selection for third generation cephalosporins.

Authors:  J H Yuk-Choi; C H Nightingale; T W Williams
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

2.  Comparative pharmacokinetics of ceftazidime in young, healthy and elderly, acutely ill males.

Authors:  B Ljungberg; I Nilsson-Ehle
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of antibacterial drugs in the elderly. Implications for selection and dosage.

Authors:  B R Meyers; P Wilkinson
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.